Are You in Control of Your Data

New Hepatitis C Assay: an Important Aid in Diagnosis and Management

Roche Elecsys anti-HCV II

Roche extend serology panel to include a new generation Elecsys anti-HCV II, optimising workflows, saving costs and providing accurate, rapid results.

With an estimated 216,000 individuals chronically infected in the UK (England 161,000, Northern Ireland 4,000, Scotland 39,000, Wales 12,000), hepatitis C (HCV) remains a major public health problem; and HCV-related end stage liver disease and mortality continue to increase1. The Health Protection Agency states that it is necessary to sustain and enhance efforts to raise awareness, prevent new infections, increase diagnosis, and treat more individuals with infection.1

The new Roche Elecsys® anti-HCV II assay can play an effective part in this strategy, as it is used to demonstrate the presence of antibodies against HCV during acute and chronic stages of disease, and after a passed infection.

Due to the high rate of asymptomatic infections, clinical diagnosis of hepatitis C is difficult and screening assays are of major importance.2 The Roche Elecsys anti-HCV II assay provides 100% clinical sensitivity3 for all known genotypes, leading to early detection of infection and patient-oriented decision making.

With high specificity in blood donors (99.84%)4,5 and samples from clinical routine, pregnant women and dialysis patients, use of the Elecsys anti-HCV II assay increases laboratory testing efficiencies. To optimise workflows and provide operational cost savings, the ready-to-use liquid reagents have a long onboard stability of 31 days on all Roche immunoassay platforms.

The new assay complements the Roche serology assay menu that includes assays for Hepatitis A, Hepatitis B, Hepatitis C, HIV, TORCH, Herpes, Syphilis and other infectious diseases.

For further information, please telephone 01444 256000 or visit the Roche website at www.roche.co.uk.

References
1. Hepatitis C in the UK 2011. London: Health Protection Agency, Colindale July 2011.
2. Di Bisceglie, A.M. (1997). Hepatitis C and hepatocellular carcinoma. Hepatology, 2 6(3 Suppl 1): 34S-8S.
3. Elecsys Anti-HCV II assay CE evaluation data. Roche 2011
4. Esteban J., van Helden J., Alborino F., Cellerai C., Eiras A., Ghisetti V., Imdahl R., Wetlitzky O., Segovia M., Schennach H., Muehlbacher A. Elecsys Anti-HCV II: a sensitive and specific assay for diagnosing hepatitis C virus (HCV) infection. Hepatology International. 2012. Volume 6. Number 1; PP11-014.
5. Strader, D.B., Wright, T., Thomas, D.L., Seeff, L.B. (2004). Diagnosis, management and treatment of hepatitis C. Hepatology, 39 (4): 1147-71.


     
Tags: Hepatitis C

Date Published: April 2, 2012

Source article link: Roche Diagnostics » company contact details
Join us on Google+

© 2001 - 2017 Rapid Test Methods Ltd • Please join us on Twitter, Facebook and LinkedIn • RSS Feed